{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:29:04Z","timestamp":1780734544246,"version":"3.54.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to investigate the combined effect of CYP3A5*3, CYP3A4*22, and <jats:italic toggle=\"yes\">POR*28<\/jats:italic> genetic polymorphisms on tacrolimus and cyclosporine dose requirements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>One hundred thirty renal transplant patients placed on either tacrolimus or cyclosporine were recruited, where the effect of CYP3A5*3, CYP3A4*22, and POR*28 genetic polymorphisms on their dose requirements were studied at days 14, 30, and 90 post-transplantations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The POR*28 allele frequency in the studied population was 29.61%. The tacrolimus dose-adjusted trough concentration ratio (C0\/D) was significantly lower in the fast metabolizers group (<jats:italic toggle=\"yes\">CYP3A5*1\/POR*28(CT\/TT<\/jats:italic>) carriers) than in the poor metabolizers group (<jats:italic toggle=\"yes\">CYP3A5*3\/*3\/CYP3A4*22<\/jats:italic> carriers) throughout the study (14, 30, and 90 days) (<jats:italic toggle=\"yes\">P =<\/jats:italic> 0.001, &lt;0.001, and 0.003, respectively). Meanwhile, there was no significant effect of this gene combination on cyclosporine C0\/D.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Combining the <jats:italic toggle=\"yes\">CYP3A5*3, POR*28<\/jats:italic>, and <jats:italic toggle=\"yes\">CYP3A4*22<\/jats:italic> genotypes can have a significant effect on early tacrolimus dose requirements determination and adjustments. However, it does not have such influence on cyclosporine dose requirements.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000516","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T05:00:14Z","timestamp":1701752414000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients"],"prefix":"10.1097","volume":"34","author":[{"given":"Abdel-Hameed IM","family":"Ebid","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina A.","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Misr International University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neama M.","family":"Lotfy","sequence":"additional","affiliation":[{"name":"Department of Technology of Medical Laboratory, Faculty of Applied Health Sciences Technology, Badr University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"El-Sharkawy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine & Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy.","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":"In vitro metabolism of cyclosporine a by human kidney CYP3A5.","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-409X(97)00043-4","article-title":"Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.","volume":"27","author":"Hebert","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing.","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"674117","DOI":"10.3389\/fphar.2021.674117","article-title":"Effect of CYP3A4, CYP3A5, MDR1 and POR genetic polymorphisms in immunosuppressive treatment in Chilean kidney transplanted patients.","volume":"12","author":"Contreras-Castillo","year":"2021","journal-title":"Front Pharmacol"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":"In vitro metabolism of cyclosporine a by human kidney CYP3A5.","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.11.90","article-title":"Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors\u00e2\u20acTM dose requirements and trough blood levels in stable renal transplant patients.","volume":"12","author":"Elens","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2013.01.010","article-title":"NADPH P450 oxidoreductase: structure, function, and pathology of diseases.","volume":"138","author":"Pandey","year":"2013","journal-title":"Pharmacol Ther"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2217\/pgs.11.77","article-title":"The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.","volume":"12","author":"de Jonge","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1073\/pnas.0711621105","article-title":"Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations.","volume":"105","author":"Huang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/FPC.0b013e32833225e7","article-title":"The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.","volume":"19","author":"Oneda","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FTD.0b013e31829da6dd","article-title":"Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine a in renal transplant patients.","volume":"36","author":"Elens","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","article-title":"The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.","volume":"70","author":"Lunde","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"728","DOI":"10.5414\/CP202152","article-title":"The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.","volume":"53","author":"Zhang","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus.","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation.","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist pharmacokinetics of calcineurin inhibitors.","volume":"2","author":"Schiff","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/FPC.0000000000000095","article-title":"Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.","volume":"24","author":"Kuypers","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3389\/fphar.2020.01218","article-title":"CYP3A5 gene-guided tacrolimus treatment of living-donor Egyptian kidney transplanted patients.","volume":"11","author":"Mendrinou","year":"2020","journal-title":"Front Pharmacol"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.4103\/1319-2442.121268","article-title":"The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.","volume":"24","author":"Shilbayeh","year":"2013","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2217\/pgs.15.138","article-title":"Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.","volume":"16","author":"Aouam","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/17425255.2016.1170808","article-title":"Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: Recent developments and ethnic considerations.","volume":"12","author":"Tang","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.transproceed.2012.10.023","article-title":"Genetic differences in native americans and tacrolimus dosing after kidney transplantation.","volume":"45","author":"Chakkera","year":"2013","journal-title":"Transplant Proc"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32830054ac","article-title":"Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.","volume":"18","author":"Agrawal","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/pgs-2020-0140","article-title":"Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population.","volume":"22","author":"Mutawi","year":"2021","journal-title":"Pharmacogenomics"},{"key":"R32-20250808","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects.","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/FTD.0000000000000542","article-title":"Impact of POR and CYP3A5 polymorphisms on trough concentration to dose ratio of tacrolimus in the early post-operative period following kidney transplantation.","volume":"40","author":"Phupradit","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FTD.0000000000000267","article-title":"A lack of significant effect of POR*28 allelic variant on tacrolimus exposure in kidney transplant recipients.","volume":"38","author":"Jannot","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R35-20250808","first-page":"483","article-title":"Association of CYP3A5 and POR polymorphisms with the maintenance tacrolimus dosage requirement in Thai recipients of kidney transplants.","volume":"10","author":"Veerakikosol","year":"2016","journal-title":"Asian Biomed"},{"key":"R36-20250808","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/FTD.0000000000000442","article-title":"Effect of age and allele variants of CYP3A5, CYP3A4, and POR genes on the pharmacokinetics of cyclosporin a in pediatric renal transplant recipients from serbia.","volume":"39","author":"Cvetkovi\u0107","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R37-20250808","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","article-title":"Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.","volume":"34","author":"Dai","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R38-20250808","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.09.7","article-title":"Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.","volume":"10","author":"Gomes","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R39-20250808","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/FPC.0b013e32833e0cb5","article-title":"Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.","volume":"20","author":"Agrawal","year":"2010","journal-title":"Pharmacogenet Genomics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:01:19Z","timestamp":1754654479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000516","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}